Study Questions Tests Used to Spot Heart Risks in Kidney PatientsLast Updated: March 15, 2011. Value of commonly used 'biomarkers' lack conclusive evidence, researchers say.
By Serena Gordon
TUESDAY, March 15 (HealthDay News) -- People with chronic kidney disease routinely undergo tests to measure blood levels of phosphorous, calcium and parathyroid hormone, to assess their risk of heart disease.
However, a new analysis of research stretching back more than 60 years casts doubt on the usefulness of some of those tests.
Researchers found little evidence to support the notion that these "biomarkers" can diagnose or prevent potential heart trouble, especially in the case of calcium and parathyroid hormone. The analysis did confirm an association between high levels of phosphorus in the blood and mortality in people with kidney disease.
"The studies that show connections between phosphorus, calcium and parathyroid hormone with important health outcomes [death and cardiovascular disease] are too few and suboptimal. Therefore, they cannot provide good evidence for definite target levels, particularly for calcium and parathyroid hormone," said study senior author Dr. Giovanni FM Strippoli, scientific director of Diaverum and renal research coordinator at the Mario Negri Sud Consortium in S. Maria Imbaro, Italy.
"People with kidney disease have mortality rates much higher than the general population. The key problem, however, is that mortality in these patients has not decreased, despite several years of new treatments becoming available," he noted.
One problem is that "risk factors for disease have become confused with the disease itself," Strippoli said. "Now, it appears that many of the risk factors we have identified so far either are not really risk factors, or we have no drugs to appropriately treat them to improve health outcomes."
The findings are published in the March 16 issue of the Journal of the American Medical Association.
About 26 million Americans have chronic kidney disease, according to the National Kidney Foundation, and heart disease remains a major cause of death in people with chronic kidney disease.
Current clinical practice guidelines recommend testing for phosphorus, calcium and parathyroid levels in the blood, and treating abnormal levels of these biomarkers.
For the current study, the researchers reviewed all available literature from 1947 through 2010. They found 47 studies of these biomarkers to include in their analysis.
The team found that the risk of death increased 18 percent for each 1 milligram per deciliter increase in serum [blood] phosphorous. However, they found no association between mortality and parathyroid hormone levels or calcium levels.
Strippoli added that there were no good studies conducted to assess whether or not the treatment of high phosphorus levels could have an impact on the risk of death.
"The idea that we can measure things in the blood in people with chronic kidney disease and make very informed, individualized treatment decisions for patients should be dispelled," said Dr. Bryan Kestenbaum, author of an accompanying editorial in the same issue of the journal.
There are plausible biological reasons for suspecting that phosphorous and calcium could increase the risk of heart disease, as they may affect the flexibility of vessel walls. Parathyroid hormone can have direct effects on heart cells and may make them grow abnormally, he explained, but added that no one can show a direct cause-and-effect relationship for any of these substances.
"Even though this analysis found an association between increased phosphorus levels and mortality, we just don't know if there's cause and effect. Is it the phosphate that causes the increased risk, or is it something about people with high phosphate levels that makes them have a higher risk?" said Kestenbaum, an associate professor in medicine and epidemiology at the Kidney Research Institute at the University of Washington in Seattle.
He added that the challenge for physicians is to try to figure out what to do now. The treatment to lower phosphate levels is simple and has a very low side effect profile. And, because there's some evidence that people with high phosphorus levels have an increased cardiovascular risk, most physicians would "err on the side of treating." But, he said, there's really "no proof that treatment would lower the risk. We really need a randomized, controlled trial to assess the risk," he said.
Strippoli agreed that a randomized clinical trial of a phosphate-lowering drug is the only way to know for sure if there's a cause-and-effect relationship.
He also believes that there needs to be a shift in medicine away from treating blood biomarkers.
"Times have changed. In the past, our patients were really very compromised. Nowadays, they are better treated overall, perhaps meaning that less emphasis on the micromanagement of individual biomarkers is required. We need to treat diseases, not biomarkers."
Learn more about chronic kidney disease from the National Kidney Foundation.
SOURCES: Giovanni FM Strippoli, M.D., Ph.D., M.P.H., scientific director, Diaverum and renal research coordinator, Mario Negri Sud Consortium, S. Maria Imbaro, Italy; Bryan Kestenbaum, M.D., M.S., associate professor, medicine and epidemiology, Kidney Research Institute, University of Washington, Seattle; March 16, 2011, Journal of the American Medical Association